Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Protalix BioTherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:00 A.M. EDT REVENUES FROM SELLING GOODS INCREASED TO $19.8 MILLION IN THE SECOND QUARTER OF 2026, UP $4.4 MILLION FROM THE SECOND QUARTER OF 2025, DRIVEN PRIMARILY BY SALES OFELFABRIO TOTAL REVENUE CLIMBED TO $53.6 MILLION, YEAR TO DATE, FROM $25.8 MILLION FOR THE SAME PERIOD IN 2025, WHICH INCLUDES THE PREVIOUSLY REPORTED $25.0 MILLION CHIESI MILESTONE PAYMENT YEAR-TO-DATE, THE COMPANY ACHIEVED PROFITABILITY WITH A NET INCOME OF $22.1 MILLION THE COMPANY REITERATES FULL-YEAR 2026 GUIDANCE OF $78.0 MILLION TO $83.0 MILLION IN TOTAL REVENUE PRX-115 PHASE 2 STUDY CONTINUES TO ADVANCE AS PLANNED, WITH TOP-LINE RESULTS ANTICIPATED IN THE SECOND HALF OF 2027 CASH, CASH EQUIVALENTS, AND SHORT-TERM BANK DEPOSITS WERE $40.7 MILLION AS OF JUNE 30, 2026, PROVIDING SUFFICIENT CAPITAL TO FUND ONGOING OPERATIONS INCLUDING THE PHASE 2 RELEASE CLINICAL TRIAL OF PRX-115 CARMIEL, ISRAEL, AUG. 12, 2026 /PRNEWSWIRE/ -- PROTALIX BIOTHERAPEUTICS, INC. (NYSE AMERICAN: PLX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, PRODUCTION, AND COMMERCIALIZATION OF INNOVATIVE THERAPEUTICS FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS AND CLINICAL UPDATE.

PROTALIX BIOTHERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL AND BUSINESS RESULTS

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:00 A.M. EDT CARMIEL, ISRAEL, AUG. 5, 2026 /PRNEWSWIRE/ -- PROTALIX BIOTHERAPEUTICS, INC. (NYSEAMERICAN: PLX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, PRODUCTION, AND COMMERCIALIZATION OF INNOVATIVE THERAPEUTICS FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE30, 2026 AND PROVIDE A BUSINESS UPDATE ON AUGUST12, 2026.

PROTALIX BIOTHERAPEUTICS TO ANNOUNCE SECOND QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE ON AUGUST 12, 2026

COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:00 A.M. EDT ELFABRIO COMMERCIAL EXECUTION CONTINUES FOLLOWING EUROPEAN COMMISSION APPROVAL OF THE 2 MG/KG EVERY4WEEKS (E4W) DOSING REGIMEN; $25 MILLION MILESTONE RECEIVED FROM CHIESI PRX115 PHASE 2 STUDY CONTINUES TO ADVANCE AS PLANNED WITH TOPLINE RESULTS ANTICIPATED IN THE SECOND HALF OF 2027 THECOMPANY REAFFIRMS ITS PREVIOUSLY STATED 2026 REVENUE GUIDANCE OF $78.0  $83.0 MILLION INCLUDING THE $25.0 MILLION MILESTONE RECEIVED FROM CHIESI CASH, CASH EQUIVALENTS, AND SHORTTERM BANK DEPOSITS WERE $51 MILLION AS OF MARCH 31, 2026, PROVIDING SUFFICIENT CAPITAL TO FUND ONGOING OPERATIONS INCLUDING THE PHASE 2 RELEASE CLINICAL TRIAL OF PRX-115 CARMIEL, ISRAEL, MAY 13, 2026 /PRNEWSWIRE/ -- PROTALIX BIOTHERAPEUTICS, INC. (NYSE AMERICAN: PLX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, PRODUCTION, AND COMMERCIALIZATION OF INNOVATIVE THERAPEUTICS FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS AND CLINICAL UPDATE.

PROTALIX BIOTHERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL AND BUSINESS RESULTS

COMPANY TO HOST CONFERENCE CALL AND WEBCAST AT 8:00 A.M. EDT CARMIEL, ISRAEL, MAY 6, 2026 /PRNEWSWIRE/ -- PROTALIX BIOTHERAPEUTICS, INC. (NYSEAMERICAN: PLX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, PRODUCTION, AND COMMERCIALIZATION OF INNOVATIVE THERAPEUTICS FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THAT IT WILL RELEASE ITS FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH31, 2026 AND PROVIDE A BUSINESS UPDATE ON MAY13, 2026.

PROTALIX BIOTHERAPEUTICS TO ANNOUNCE FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE ON MAY 13, 2026

COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:00 A.M. EDT THE EUROPEAN COMMISSION (EC) APPROVED THE 2MG/KG EVERY-4-WEEKS (E4W) DOSING REGIMEN FOR ELFABRIO IN ADULTS LIVING WITH FABRY DISEASE PROVIDING A MEANINGFUL REDUCTION IN TREATMENT BURDEN WITHOUT COMPROMISING EFFICACY THE EC APPROVAL TRIGGERED THE COMPANY'S ENTITLEMENT TO A $25.0 MILLION MILESTONE PAYMENT FROM CHIESI, STRENGTHENING THE COMPANY'S CASH POSITION AND SUPPORTING AN EXPECTED CASH BALANCE OF APPROXIMATELY $50.0 MILLION BY APRIL 2026 BASED ON CURRENT ESTIMATES, MANAGEMENT EXPECTS TOTAL REVENUES IN 2026 TO RANGE FROM APPROXIMATELY $78.0 MILLION TO $83.0 MILLION INCLUDING THE $25.0 MILLION PAYMENT REFERENCED ABOVE THE PHASE 2 CLINICAL TRIAL OF PRX115 IS ACTIVELY ENROLLING; THE COMPANY BELIEVES PRX-115 HAS THE POTENTIAL TO BE A BEST-IN-CLASS THERAPY, IMPROVING UNCONTROLLED GOUT PATIENTS' COMPLIANCE AND OUTCOMES CONTINUED STRATEGIC FOCUS ON RARE RENAL DISEASES TO BUILD A PIPELINE THROUGH INNOVATION AND PARTNERSHIPS CARMIEL, ISRAEL, MARCH 18, 2026 /PRNEWSWIRE/ --PROTALIX BIOTHERAPEUTICS, INC. (NYSEAMERICAN: PLX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, PRODUCTION AND COMMERCIALIZATION OF INNOVATIVE THERAPEUTICS FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY REPORTED FINANCIAL RESULTS FOR THE FISCAL YEAR ENDEDDECEMBER31, 2025, AND PROVIDED A BUSINESS AND CLINICAL UPDATE.

PROTALIX BIOTHERAPEUTICS REPORTS FISCAL YEAR 2025 FINANCIAL AND BUSINESS RESULTS

THIS PRESS RELEASE IS INTENDED FOR US AUDIENCES FOR TRANSPARENCY RELATIVE TO GLOBAL NEWS FOR THE FABRY COMMUNITY. THIS DOSING REGIMEN FOR ELFABRIO IS NOT APPROVED IN THE US. IN THE US, THE FDA-APPROVED DOSING REGIMEN REMAINS 1MG/KG EVERY 2 WEEKS. PLEASE SEE IMPORTANT SAFETY INFORMATION BELOW AND THE FULL PRESCRIBING INFORMATION , INCLUDING BOXED WARNING.

CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS ANNOUNCE EUROPEAN COMMISSION APPROVAL OF ADDITIONAL DOSING REGIMEN OF EVERY FOUR WEEKS FOR ELFABRIO (PEGUNIGALSIDASE ALFA)

ORAL PRESENTATION PROVIDES ADDITIONAL SCIENTIFIC RATIONALE ON KRABBE DISEASE, ONE OF FOUR LSDS IN THE PHASE 2 SOTERIA BASKET TRIAL DESIGNED TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF LEAD DRUG CANDIDATE PLX-200 ORAL PRESENTATION PROVIDES ADDITIONAL SCIENTIFIC RATIONALE ON KRABBE DISEASE, ONE OF FOUR LSDS IN THE PHASE 2 SOTERIA BASKET TRIAL DESIGNED TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF LEAD DRUG CANDIDATE PLX-200

POLARYX TO PRESENT LATE-BREAKER DATA RELATED TO SOTERIA AT THE 22ND ANNUAL WORLDSYMPOSIUM AS COMPANY PREPARES FOR SOTERIA TRIAL LAUNCH

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES A POSITIVE OPINION FOLLOWING RE-EXAMINATION, WHICH WILL BE REVIEWED BY THE EUROPEAN COMMISSION (EC), WITH A DECISION ANTICIPATED BY MARCH 2026

CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS RECEIVE POSITIVE CHMP OPINION FOR AN ADDITIONAL DOSING REGIMEN OF 2MG/KG BODY WEIGHT EVERY-FOUR-WEEKS FOR ELFABRIO (PEGUNIGALSIDASE ALFA)  IN THE EU

CHIESI GLOBAL RARE DISEASES AND PROTALIX BIOTHERAPEUTICS RECEIVE POSITIVE CHMP OPINION FOR AN ADDITIONAL DOSING REGIMEN OF EVERY FOUR WEEKS FOR ELFABRIO (PEGUNIGALSIDASE ALFA) IN THE EU

CARMIEL, ISRAEL, JAN. 5, 2026 /PRNEWSWIRE/ -- PROTALIX BIOTHERAPEUTICS, INC. (NYSE AMERICAN: PLX), A BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, PRODUCTION AND COMMERCIALIZATION OF INNOVATIVE THERAPEUTICS FOR RARE DISEASES WITH SIGNIFICANT UNMET NEEDS, TODAY ANNOUNCED THE FOLLOWING UPDATE FROM PRESIDENT AND CHIEF EXECUTIVE OFFICER, DROR BASHAN, TO ITS STOCKHOLDERS. DEAR PROTALIX STOCKHOLDERS, AS WE LOOK FORWARD TO 2026, WE REMAIN FOCUSED ON BUILDING WITH OUR PARTNERS A GROWING, PROFITABLE BUSINESS AND AN INNOVATIVE PIPELINE FOR PATIENTS WITH HIGH-NEED RARE DISEASES.

Protalix BioTherapeutics, Inc.

PLX

Price

Financial Reports

No items found.

Press Releases

Protalix BioTherapeutics, Inc.

PLX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PLX